Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0609 • ACR Convergence 2021
Challenges of Caring for Patients with Inflammatory Arthritis Experiencing Homelessness: Preliminary (12- Month) Follow-up Observations and Identification of Certain Barriers to Care
Baljeet Rai¹, Nicole Zagelbaum Ward², Abhimanyu Amarnani², Corinne Feldman², Brett Feldman² and Richard Panush², ¹LAC+USC Medical Center, Modesto, CA, ²LAC+USC Medical Center, Los Angeles, CA
Background/Purpose: Homelessness is a public health crisis. Those with housing insecurity have unique barriers to healthcare that confound their outcomes. Because of the paucity of…
Abstract Number: 0788 • ACR Convergence 2021
Red Cell Distribution Width Is Associated with Baseline 25-hydroxyvitamin D Level Before Methotrexate Therapy in Rheumatoid Arthritis
Shahdi Malakooti¹, Brigid Wilson², Taissa Bej², Lenche Kostadinova³, Alyssa Lange², Megan O'Mara², David Zidar², Maya Mattar⁴ and Donald Anthony⁵, ¹Case Western Reserve University, UH Cleveland Medical Center, VA Medical Center, Cleveland, OH, ²VA Medical Center, Cleveland, OH, ³UH Cleveland Medical Center, VA Medical Center, Cleveland, OH, ⁴Louis Stokes VA Medical Center, Mayfield Heights, OH, ⁵Case, VA, Metro, Chardon, OH
Background/Purpose: Peripheral blood red cell distribution width (RDW) correlates with disease activity in rheumatoid arthritis (RA) and is associated with subsequent mortality in non-RA patient…
Abstract Number: 0804 • ACR Convergence 2021
Validation of the 2010 ACR/EULAR Classification Criteria of Rheumatoid Arthritis (RA) in a Nursing-led Triage Clinic
Ching Man Tsang¹, Chi Chiu Mok², Kar Li Chan³, Sau Mei TSE¹ and Ling Yin Ho¹, ¹Tuen Mun Hospital, Hong Kong, Hong Kong, ²Tuen Mun Hospital, Hong Kong, China, ³Tuen Mun Hospital, Hong Kong
Background/Purpose: To shorten the waiting time to see rheumatologists, a nurse-led triage clinic was established in our hospital in September 2018 to triage new referrals…
Abstract Number: 0822 • ACR Convergence 2021
Local Tolerance of GP2017, an Adalimumab Biosimilar with Low Citrate Concentration Formulation, in Healthy Volunteers and Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis
Piotr Wiland¹, Andrew Blauvelt², Lena Lemke³, Oliver von Richter⁴, Alison Balfour⁴, Fabricio Furlan⁴ and Norman Gaylis⁵, ¹Department of Rheumatology and Internal Medicine, Medical University, Wroclaw, Poland, ²Oregon Medical Research Center, Portland, ³Hexal AG (A Sandoz company), Holzkirchen,Germany, Holzkirchen, Germany, ⁴Hexal AG (A Sandoz company), Holzkirchen, Germany, Holzkirchen, Germany, ⁵Arthritis and Rheumatic Disease Specialties, Aventura, FL
Background/Purpose: Adalimumab (ADL) can be self-administered every 2 weeks as a subcutaneous (s.c.) injection in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and psoriasis…
Abstract Number: 0839 • ACR Convergence 2021
Comparative Treatment Effectiveness in Rheumatoid Arthritis with and Without Concomitant Sjögren’s Syndrome – Results from the Swiss Clinical Quality Management Cohort
Lisa Christ¹, Seraphina Kissling², Ruediger B. Mueller³, Axel Finckh⁴, Benjamin Fisher⁵, Britta Maurer¹, Burkhard Moeller⁶ and Florian Kollert¹, ¹Department of Rheumatology and Immunology, University Hospital (Inselspital) and University of Bern, Bern, Switzerland, ²Statistics and Data Management Group, Swiss Clinical Quality Management Foundation, Zurich, Switzerland, ³Clinic of Rheumatology, Medical University Hospital Aarau, Aarau, Switzerland, ⁴University Hospital of Geneva, Geneve - Vesenaz, Switzerland, ⁵Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham; National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre and Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ⁶Inselspital - University Hospital Bern, Bern, Switzerland
Background/Purpose: The variety of treatment options in RA contrasts with a lack of personalized medicine. The presence of concomitant SjS might be associated with differerences…
Abstract Number: 0983 • ACR Convergence 2021
Anti-S1 Antibodies After Vaccination with Anti SARS-CoV-2 mRNA Vaccines in Patients with Rheumatoid Arthritis Differ in Magnitude and Kinetics from Healthy Controls: Results from a Prospective, Observational Controlled Study
Andrea Rubbert-Roth¹, Nicolas Vuilleumier², Burkhard Ludewig³, Kristin Schmiedeberg⁴, Yella Rottlaender⁴, Ian Pirker⁵ and Johannes VonKempis⁶, ¹Kantonspital St Gallen, St.Gallen, Switzerland, ²Departement Diagnostique, University of Geneva, Switzerland, Geneva, Switzerland, ³Institute of Immunobiology, Cantonal Hospital St Gallen, St Gallen, Switzerland, ⁴Division of Rheumatology, Cantonal Hospital St Gallen, St Gallen, Switzerland, ⁵Kantonsspital St. Gallen, St.Gallen, Switzerland, ⁶Division of Rheumatology and Immunology, St. Gallen, Switzerland
Background/Purpose: Long-term vaccine-induced immunity to SARS-CoV-2 is critical to combat the pandemic. Vaccination against anti SARS-CoV-2 is recommended in patients with rheumatic diseases, but limited…
Abstract Number: 1071 • ACR Convergence 2021
Experiences Using Wearable Technology by Persons with Rheumatoid Arthritis Participating in a Physical Activity Counselling Intervention Study: A Relational Ethics Analysis
Jenny Leese¹, Siyi Zhu², Anne Townsend³, Catherine L. Backman¹, Laura Nimmon¹ and Linda Li¹, ¹University of British Columbia, Vancouver, BC, Canada, ²Sichuan University, Chengdu, China (People's Republic), ³Lancaster University, Lancaster, United Kingdom
Background/Purpose: Using wearables to self-monitor physical activity is a promising approach to support self-management among persons with arthritis. Evidence indicates, from perspectives of persons with…
Abstract Number: 1199 • ACR Convergence 2021
Ultrasound in Clinically Suspect Arthralgia: The Role of Power Doppler to Predict Rheumatoid Arthritis Development
Katerine López¹, Isabel Castrejón¹, Juan Carlos Nieto¹, Javier Rivera¹, Teresa González², Fernando Montero¹, Carlos González³, Jose Maria Alvaro-Gracia¹ and Juan Molina⁴, ¹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²H Gregorio Maraon, Madrid, Spain, ³CEIMI, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁴Hospital General Universitario Gregorio Maran, Madrid, Spain
Background/Purpose: It is of great importance to identify patients with clinically suspect arthralgia (CSA) who will develop rheumatoid arthritis (RA) or other inflammatory arthritis (IA)…
Abstract Number: 1215 • ACR Convergence 2021
Development of a Multivariable Prediction Model for Treatment Response to Etanercept in a Multi-centre Cohort of Patients with Established RA
Michael Stadler¹, Stephanie Ling², Nisha Nair², John Isaacs³, Kimme Hyrich², Ann Morgan⁴, Anthony Wilson⁵, Darren Plant², Anne Barton² and John Bowes², ¹University of Manchester, Preston, United Kingdom, ²University of Manchester, Manchester, United Kingdom, ³Newcastle University, Newcastle upon Tyne, United Kingdom, ⁴University of Leeds, Leeds, United Kingdom, ⁵Center for Arthritis Research, Conway Institute, University College Dublin, Dublin, Ireland
Background/Purpose: RA patients who respond inadequately to first-line DMARDs usually progress to a biologic DMARD. Treatment response to both DMARDs and biologics is heterogeneous within…
Abstract Number: 1231 • ACR Convergence 2021
Consistent Impact of Autoantibody Enrichment Across All ACR Core Measures in Early Rheumatoid Arthritis Treated with Abatacept: Data from a Large Pooled Analysis of 4 Randomized Controlled Trials
Philip Conaghan¹, Sang Hee Park², Mirko Fillbrunn³, Karissa Lozenski², Vadim Khaychuk², Kaleb Michaud⁴, Elyse Swallow³, Henry Lane³, Ha Nguyen³ and Janet Pope⁵, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Bristol Myers Squibb, Princeton, NJ, ³Analysis Group, Inc., Boston, MA, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Western Ontario, London, ON, Canada
Background/Purpose: Biomarkers play an important role in RA and can help guide treatment decisions. Previous studies have suggested differential treatment efficacy of abatacept (ABA) in…
Abstract Number: 1247 • ACR Convergence 2021
Plasma Cell-free DNA Is a Useful Biomarker for Tocilizumab Therapy in Rheumatoid Arthritis
Teppei Hashimoto¹, Yuichi Yokoyama², Takahiro Yoshikawa³, Tetsuya Furukawa⁴, Naoto Azuma⁵, Akira Hashiramoto⁶ and Kiyoshi Matsui⁷, ¹Hyogo College of Medicine, Kobe, Hyogo, Japan, ²Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, ³Hyogo College of Medicine, Nishinomiya, Japan, ⁴Hyogo college of Medicine, Nishinomiya, Hyogo, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan, ⁶Kobe University, Kobe, Japan, ⁷Hyogo College of Medicine, Nishinomiya-city, Hyogo, Japan
Background/Purpose: Endogenous DNA derived from nuclei is released into the blood circulation as cell-free DNA (cfDNA) following cell damage or death. cfDNA is associated with…
Abstract Number: 1444 • ACR Convergence 2021
Baseline Factors Associated with the Development of Nausea and Alopecia over One Year in Patients Starting Methotrexate for Rheumatoid Arthritis
Ahmad Sherbini¹, James Gwinnutt¹, Kimme Hyrich¹ and Suzanne Verstappen², ¹University of Manchester, Manchester, United Kingdom, ²School of Social Sciences, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Methotrexate (MTX) is the first-line treatment in the management of patients with rheumatoid arthritis (RA) due to its good efficacy. However, certain adverse events,…
Abstract Number: 1610 • ACR Convergence 2021
“You Can’t Touch, You Can’t Bond”: COVID-19 and Telehealth Impacts on Communication, Goals, and Experience of Care for Persons with Rheumatoid Arthritis and Their Clinicians
Elizabeth Hulen¹, Christopher Larsen², Rachel Matsumoto², Patricia Katz³ and Jennifer Barton⁴, ¹VA Portland Health Care System, Portland, OR, ²Center to Improve Veteran Involvement in Care/VA Portland Health Care System, Portland, OR, ³University of California San Francisco, San Francisco, CA, ⁴VA Portland Health Care System/OHSU, Portland, OR
Background/Purpose: A rapid shift to telehealth visits has been a key part of health system response to the ongoing COVID-19 pandemic. This study explores the…
Abstract Number: 1662 • ACR Convergence 2021
Unrecognised, Subclinical, Structural or Functional Lung Changes in Rheumatoid Arthritis Is Associated with a Higher Risk of Developing Serious Respiratory Tract Infection
Benjamin Worcester¹, Dorothy Wang², Susan Morton³ and Michelle Leech⁴, ¹Monash Health, Melbourne, Australia, ²Melbourne Health, Clayton, Australia, ³Monash Health, Clayton, Australia, ⁴Monash Medical Centre, Australia, Australia
Background/Purpose: The incidence of lung disease within the rheumatoid arthritis is well described and likely underestimated. Additionally, RA patients are at higher risk for developing…
Abstract Number: 1678 • ACR Convergence 2021
Favorable Balance of Benefit and Harm of Long-Term, Low Dose Prednisolone Added to Standard Treatment in Rheumatoid Arthritis Patients Aged 65+: The Pragmatic, Multicenter, Placebo-Controlled GLORIA Trial
Maarten Boers¹, Linda Hartman¹, Daniela Opris-Belinski², Reinhard Bos³, Marc Kok⁴, Jose Pereira da Silva⁵, Ed Griep⁶, Ruth Klaasen⁷, Cornelia F. Allaart⁸, Paul Baudoin⁹, Hennie Raterman¹⁰, Zoltan Szekanecz¹¹, Frank Buttgereit¹², Pavol Masaryk¹³, L. Thomas Klausch¹, Sabrina Paolino¹⁴, Annemarie Schilder³, Willem Lems¹⁵ and Maurizio Cutolo¹⁴, ¹Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ²Carol Davila University, Bucharest, Romania, ³Medical Center Leeuwarden, Leeuwarden, Netherlands, ⁴Maasstad Hospital, Rotterdam, Netherlands, ⁵University of Coimbra | UC · Clínica Universitária de Reumatologia. Faculty of Medicine, Columbia, Portugal, ⁶Antonius Hospital, Sneek, Netherlands, ⁷Meander Medical Center, Amersfoort, Netherlands, ⁸Leiden University Medical Center, Leiden, Netherlands, ⁹Reumazorg Flevoland, Emmeloord, Netherlands, ¹⁰Northwest Clinics, Alkmaar, Netherlands, ¹¹Division of Rheumatology, University of Debrecen, Faculty of Medicine, Debrecen, Hungary, ¹²Charité – Universitätsmedizin Berlin, Berlin, Germany, ¹³National Institute for the Rheumatic Diseases, Bratislava, Slovakia, ¹⁴Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa, Italy, ¹⁵VUmc, Amsterdam, Netherlands
Background/Purpose: Low-dose glucocorticoid (GC) therapy is widely used in rheumatoid arthritis (RA) but the balance of benefit and harm is still unclear. We studied the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].